Материалов:
1 081 645

Репозиториев:
30

Авторов:
761 409

По вашему запросу найдено документов: 23

Страница 2 из 3

Economic challenges of oncological diseases’ pharmacotherapy
Ushkalova E. A.
as to use high-quality generics and biosimilars as effective and safe as their originals, and to monitor
Use of sorption processes in the technology of drug delivery systems
Bondarev, A. V., Zhilyakova, E. T.
(medical clays, synthetic sorbents), polymers and their biosimilars. 6 groups of pharmaceutical substances
Модели флотации и гидродинамические режимы работы комбинированной флотационной техники
Ксенофонтов Б.С.
based on the principles of biosimilarity. Diagrams of various types of combined flotation equipment
International nonproprietary names for biological and biotechnological drugs
Dudchenko V.V., Popov P.I., Bunyatyan N.D., Yavorsky A.N., Merkulov V.A.
substitutes, transgenic products, vaccines, biosimilars. The conclusion was made about the need for an early
The influence of cholesterol and calcium ions on the interaction of cryoprotectors with a biological membrane model
Svechnikova V.Y., Mishukova O.V., Mironova A.G., Khomutov G.B., Marchenkova M.A., Yakovenko S.A.
. The scientific novelty of the work is in consideration of a complex biosimilar system (an egg yolk monolayer
Сравнительная оценка долгосрочной эффективности и безопасности биоаналога инфликсимаба BCD-055 и референтного инфликсимаба у пациентов с анкилозирующим спондилитом: результаты международного многоцентрового рандомизированного двойного слепого клинического исследования III фазы ASART-2
Лила, А. М., Мазуров, В. И., Покровская, Т. Г., Зонова, Е. В., Несмеянова, О. Б.
Results of a phase i open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of G lurazyme® (imiglucerase) in comparison with the reference product in healthy volunteers
Fitilev S.B., Vozzhaev A.V., Shkrebneva I.I., Kudlay D.A., Gapchenko E.V., Markova O.A., Borozinets A.Y., Kazarov A.A., Pantyushenko M.S.
of the "Pharma 2020" pharmaceutical industry development strategy, the first biosimilar of imiglucerase, the drug
Formation of copper nanoparticles with hyperbranched polyesterpolyols as template
Medvedeva O., Kambulova S., Ulakhovich N., Vorobev V., Evtyugin V., Khaldeeva E., Kutyreva M.
Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of Glurazim® (imiglucerase) in comparison with the reference product in healthy volunteers
Fitilev S.B., Vozzhaev A.V., Shkrebneva I.I., Kudlay D.A., Gapchenko E.V., Markova O.A., Borozinets A.Y., Kazarov A.A., Pantyushenko M.S.
of the “Pharma 2020” pharmaceutical industry development strategy, the first biosimilar of imiglucerase, the drug
Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial
Alexeeva, E, Horneff, G., Dvoryakovskaya, T., Denisova, R., Nikishina, I., Zholobova, E., Malievskiy, V., Santalova, G., Stadler, E., Balykova, L., Spivakovskiy, Y., Kriulin, I., Alshevskaya, A., Moskalev, A.

Страница 2 из 3

Фасеты

Партнеры

КФУ
ТГУ
Elpub
СФУ
Webpublishers

Индексация

BASE
WorldCat
OpenAIRE
EDS
core